PathoQuest, a Kurma Partners portfolio company, pioneer and global leader in Next Generation Sequencing (NGS)-based biosafety testing, announces today that it has entered into a definitive agreement to be acquired by Charles River Laboratories, a leading global provider of products and services that advance biopharmaceutical research, development, and manufacturing.
Headquartered in Paris, France, with a U.S. site in Wayne, Pennsylvania, PathoQuest supports pharmaceutical, biotech, and CDMO partners worldwide. Its proprietary iDTECT® platform delivers state-of-the-art viral safety and genetic characterization testing designed to meet the rapidly evolving needs of advanced biologic modalities, including cell and gene therapies, and vaccines.
This milestone marks a powerful new chapter for PathoQuest, reinforcing its mission to transform biosafety testing through faster, animal-free, and GMP-compliant genomic solutions. By joining forces with Charles River Laboratories, PathoQuest’s innovative technologies will benefit from a truly global footprint, accelerating adoption across the full biopharmaceutical lifecycle.
“This transaction represents a defining moment in PathoQuest’s journey,” said Jean-François Brepson, CEO of PathoQuest. “Thanks to the trust and long-term support of our investors, we have built a world-class NGS platform that is reshaping biosafety testing. Joining Charles River enables us to expand our global impact and provide our faster, animal-free, GMP-compliant solutions to even more innovators worldwide.”
“ Pathoquest is another illustration of the strong capabilities of Kurma Partners to identify groundbreaking science from European universities and to launch successful companies with strong industry and medecial needs and high impact”, said Thierry Laugel, partner at Kurma Partners.
